BillionToOne, Inc.: financial statements

BLLNNASDAQHealthcare · Services-Medical Laboratories

Price

$91.54

November 18, 2026Market cap $4.3B

What Ploutos Investor adds for BillionToOne

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 21% since Nov 4, 2026, when the 10-Q these figures come from was filed ($113.89 then, $89.54 on Nov 18, 2026). The figures date from before that move.10-Q
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+106.1% a year over 2 years

Line202320242025Average a year
Revenue $72M$153M$305M+106.1%
Cost of revenue $54M$72M$97M+33.2%
Gross profit $17M$81M$208M+246.7%
Operating income -$69M-$47M$16M
Net income -$83M-$42M$7.5M
Earnings per share -$8.45-$4.12$0.14
Earnings per share, basic -$8.45-$4.12$0.18
Margins
Gross margin 24.1%53.0%68.3%
Operating margin -96.9%-30.9%5.3%
Net margin -115.3%-27.2%2.4%

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: Prenatal $69M, Oncology –, Clinical Trial Support And Other Services $2.9M
  • 2024: Prenatal $146M, Oncology $2.9M, Clinical Trial Support And Other Services $3.7M
  • 2025: Prenatal $277M, Oncology $25M, Clinical Trial Support And Other Services $3.1M
Product202320242025Share 2025
Prenatal$69M$146M$277M91%
Oncology–$2.9M$25M8.2%
Clinical Trial Support And Other Services$2.9M$3.7M$3.1M1.0%

From the XBRL of 1 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$0 Due within 2 years$52M Leases4.0% Effective tax rate

When the debt falls due

Dec 31, 2025

Due within 2 years

$0

Principal of loans and bonds falling due, from the annual report dated December 31, 2025, without leases and interest. The filing

  • 2026: –
  • 2027: –

Leases

Dec 31, 2025

Operating leases

$51M

Finance leases

$867.0K

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

4.0%

-17.0 pts

The company paid 4.0% in tax on its profit, 17.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance

-83.0 pts

Difference the filing does not itemize

+66.0 pts

Effective rate

4.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Receivables and inventory against sales

In the quarter to Sep 30, 2026, sales were +47.2% on the same quarter a year earlier, and receivables +154.8%. Inventory was +25.9%, against +42.7% for the cost of sales.

  • Days of sales in receivables rose more than at nine in ten S&P 500 companies.
a year earlier 38 days
65 days
a year earlier 63 days
56 days

Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

Taxes: deferred and paid

The deferred part was 0.0% of the tax charge in the year to Dec 31, 2025. The rows show the last 3 years.

Cash taxes paid were 159.7% of the current tax charge in the year to Dec 31, 2025.

Deferred share, year to Dec 31, 2025$0 of $305.0K
0.0%
Deferred share, year to Dec 31, 2024$0 of $29.0K
0.0%
Deferred share, year to Dec 31, 2023$0 of $9.0K
0.0%
$487.0K paid, $305.0K current
159.7%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do BillionToOne's filings show?

These are BillionToOne's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about BLLN's financials

Didn't find what you were looking for?

Ask us
How much revenue did BLLN have in 2025?

BillionToOne had revenue of $305M and net income of $7.5M in fiscal 2025, a net margin of 2.4%.

How much debt does BLLN have?

On December 31, 2025 BillionToOne had total assets of $633M, debt of $57M and shareholders' equity of $480M.

How much free cash flow does BLLN have?

In fiscal 2025 BillionToOne had cash from operations of $25M and spent $8.9M on capital expenditure, leaving $16M of free cash flow.

Where are the figures from?

From BillionToOne, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.